WO2026013632 - ANTI-NECTIN-4 ANTIBODIES AND USES THEREOF

National phase entry is expected:
Publication Number WO/2026/013632
Publication Date 15.01.2026
International Application No. PCT/IB2025/057034
International Filing Date 11.07.2025
Title **
[English] ANTI-NECTIN-4 ANTIBODIES AND USES THEREOF
[French] ANTICORPS ANTI-NECTINE-4 ET LEURS UTILISATIONS
Applicants **
HANGZHOU BAILITE BIOPHARMACEUTICAL CO., LTD.
Inventors
YANG, Ming
ZHONG, Hongyan
LI, Hsieh
GUO, Daniel
NGUYEN, Phuong T.
Priority Data
63/670,507   12.07.2024   US
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting6424
EPO Filing, Examination, Granting141844
Japan Filing, Examination, Granting4972
South Korea Filing, Examination, Granting9879
USA Filing, Examination, Granting37890
MasterCard Visa
Total: 201,009
Contact Us
Abstract[English] This disclosure provides novel heavy chain-only antibodies, bispecific antibodies, multispecific antibodies, and fusion proteins thereof that bind to Nectin Cell Adhesion Molecule 4 (Nectin-4), related antibody-drug conjugates, related nucleic acids, related cells, related kits, related compositions, and related methods or uses.[French] La présente divulgation concerne de nouveaux anticorps de chaîne lourde unique, des anticorps bispécifiques, des anticorps multispécifiques et des protéines de fusion de ceux-ci qui se lient à la molécule d'adhésion cellulaire de nectine 4 (nectine-4), des conjugués anticorps-médicament associés, des acides nucléiques apparentés, des cellules associées, des kits associés, des compositions associées, et des procédés ou des utilisations associés.